N-Heterocyclic-Carbene-Catalyzed Redox Lactonization of o -Hydroxycinnamaldehydes and o -Hydroxycinnamyl Alcohols to Coumarins

Modern metal-catalyzed and organocatalytic methods for synthesis of coumarin derivatives: a review

Coumarin is an important pharmaceutical structural motif, abundantly found in numerous commonly used drugs. Compounds containing this core show a broad spectrum of medicinal properties and biological activities. The increasing importance and wide usages of coumarin derivatives have drawn attention to its synthetic methods, among which metal-catalyzed and organocatalytic methods have proved the most effective. Several metal-catalyzed and/or organocatalytic synthetic strategies for coumarin have been investigated and reported in recent decades. This review focuses on more recent reports on catalysis methods for synthesizing coumarin and coumarin-like structures (including light-mediated methods and nano-catalysts), exploring the mechanistic aspects, simplicity, efficiency, repeatability, and other advantages and disadvantages of these methods.

Discovery of Coumarin as Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide. Nowadays, pharmacological therapy for HCC is in urgent needs. Paclitaxel is an effective drug against diverse solid tumors, but commonly resisted in HCC patients. We recently have disclosed that microtubule affinity-regulating kinase 4 (MARK4) increases the microtubule dynamics and confers paclitaxel resistance in HCC, suggesting MARK4 as an attractive target to overcome paclitaxel resistance. Herein, we synthesized and identified coumarin derivatives 50 as a novel MARK4 inhibitor. Biological evaluation indicated compound 50 directly interacted with MARK4 and inhibited its activity in vitro, suppressed cell viability and induced apoptosis of HCC cells in a MARK4-dependent manner. Importantly, compound 50 significantly increased the drug response of paclitaxel treatment to HCC cells, providing a promise strategy to HCC treatment and broadening the application of paclitaxel in cancer therapy.